Last reviewed · How we verify
pegylated interferon-alfa
Pegylated interferon-alfa is a modified form of interferon-alfa that binds to interferon-alfa receptors on immune cells to enhance antiviral and anti-tumor immune responses.
Pegylated interferon-alfa is a modified form of interferon-alfa that binds to interferon-alfa receptors on immune cells to enhance antiviral and anti-tumor immune responses. Used for Chronic hepatitis B, Chronic hepatitis C, Certain hematologic malignancies (e.g., chronic myeloid leukemia, melanoma).
At a glance
| Generic name | pegylated interferon-alfa |
|---|---|
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Interferon |
| Target | Interferon-alfa receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Interferon-alfa is a cytokine that activates natural killer cells, macrophages, and T cells to mount antiviral and anti-proliferative responses. Pegylation (attachment of polyethylene glycol) extends the drug's half-life and reduces immunogenicity, allowing for less frequent dosing while maintaining therapeutic efficacy. This formulation is used primarily in chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Certain hematologic malignancies (e.g., chronic myeloid leukemia, melanoma)
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Depression and mood changes
- Thrombocytopenia
- Neutropenia
- Anemia
- Injection site reactions
Key clinical trials
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B (PHASE2)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: